Yndgaard S, Lippert F K, Berthelsen P G
Anaestesiologisk afdeling, Amtssygehuset i Gentofte.
Ugeskr Laeger. 1998 Apr 27;160(18):2706-9.
As the human cardiomyocyte expresses both beta 1 and beta 2 adrenoceptors it is to be expected that the inhibition of one species of receptors can be counteracted by the other. This hypothesis was tested in 40 middle-aged men scheduled for coronary artery bypass surgery. Half the patients had been treated with cardioselective beta 1 antagonists for more than three months while the 20 control patients had never been beta-blocked. The haemodynamic status after induction of a standardized fentanyl/midazolam anaesthesia and the sensitivity of the cardiovascular beta-adrenoceptors to isoprenaline titration were similar in both groups. In conclusion, patients chronically treated with cardioselective beta 1-blockers compensate for the perturbation to such a degree that their cardiovascular function is indistinguishable from patients who have never received beta-blockers.
由于人类心肌细胞同时表达β1和β2肾上腺素能受体，因此可以预期一种受体的抑制作用可被另一种受体抵消。该假设在40名计划进行冠状动脉搭桥手术的中年男性中进行了测试。一半患者接受心脏选择性β1拮抗剂治疗超过三个月，而20名对照患者从未接受过β受体阻滞剂治疗。两组在标准化芬太尼/咪达唑仑麻醉诱导后的血流动力学状态以及心血管β肾上腺素能受体对异丙肾上腺素滴定的敏感性相似。总之，长期接受心脏选择性β1阻滞剂治疗的患者对这种干扰的代偿程度使得他们的心血管功能与从未接受过β受体阻滞剂治疗的患者无法区分。
